These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10593449)

  • 1. Differential olanzapine plasma concentrations by sex in a fixed-dose study.
    Kelly DL; Conley RR; Tamminga CA
    Schizophr Res; 1999 Nov; 40(2):101-4. PubMed ID: 10593449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monitoring of serum olanzapine during antipsychotic treatment].
    Linnet K; Olesen OV
    Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Olanzapine in the first episode of schizophrenia in young adults].
    Dabkowska M
    Psychiatr Pol; 2002; 36(6 Suppl):235-41. PubMed ID: 12647444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
    Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
    J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.
    Perry PJ; Lund BC; Sanger T; Beasley C
    J Clin Psychopharmacol; 2001 Feb; 21(1):14-20. PubMed ID: 11199942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.
    Lane HY; Guo SC; Hwang TJ; Chen YS; Cheng JJ; Lee YC; Hong CJ; Hwu HG; Chang WH
    J Clin Psychopharmacol; 2002 Oct; 22(5):530-2. PubMed ID: 12352282
    [No Abstract]   [Full Text] [Related]  

  • 7. [Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].
    Jarema M; Olajossy M; Chrzanowski W; Araszkiewicz A; Landowski J; Rybakowski J; Bilikiewicz A; Bomba J; Debowska G
    Psychiatr Pol; 2003; 37(4):641-55. PubMed ID: 14560493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
    Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
    J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of fluoxetine on olanzapine pharmacokinetics.
    Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
    AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
    Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
    J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.
    Khan M; Farver D
    S D J Med; 2000 Feb; 53(2):65-7. PubMed ID: 10731859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine. Keep an eye on this neuroleptic.
    Can Fam Physician; 2000 Feb; 46():322-6, 330-6. PubMed ID: 10690489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
    Francobandiera G
    Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose olanzapine therapy in schizophrenia.
    Alao AO; Armenta WA; Yolles JC
    Ann Pharmacother; 1999 Nov; 33(11):1228. PubMed ID: 10573326
    [No Abstract]   [Full Text] [Related]  

  • 15. Intoxication with olanzapine.
    Bosch RF; Baumbach A; Bitzer M; Erley CM
    Am J Psychiatry; 2000 Feb; 157(2):304-5. PubMed ID: 10671421
    [No Abstract]   [Full Text] [Related]  

  • 16. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.
    Bizouard P; Vandel S; Kantelip JP
    Therapie; 2001; 56(4):443-5. PubMed ID: 11677871
    [No Abstract]   [Full Text] [Related]  

  • 18. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
    Rao ML; Hiemke C; Grasmäder K; Baumann P;
    Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2 receptor occupancy under recommended and high doses of olanzapine.
    Harvey EJ; Taylor DM; Flanagan RJ
    J Psychopharmacol; 2001 Sep; 15(3):213-4. PubMed ID: 11565632
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia.
    Fellows L; Ahmad F; Castle DJ; Dusci LJ; Bulsara MK; Ilett KF
    Ther Drug Monit; 2003 Dec; 25(6):682-9. PubMed ID: 14639054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.